These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 11900311)

  • 1. Pioglitazone: a review of Japanese clinical studies.
    Baba S
    Curr Med Res Opin; 2001; 17(3):166-89. PubMed ID: 11900311
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and clinical efficacy of pioglitazone.
    Hanefeld M
    Int J Clin Pract Suppl; 2001 Sep; (121):19-25. PubMed ID: 11594240
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of pioglitazone in type 2 diabetes: a randomised, placebo-controlled study in patients receiving stable insulin therapy.
    Rosenstock J; Einhorn D; Hershon K; Glazer NB; Yu S;
    Int J Clin Pract; 2002 May; 56(4):251-7. PubMed ID: 12074206
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Troglitazone: review and assessment of its role in the treatment of patients with impaired glucose tolerance and diabetes mellitus.
    Johnson MD; Campbell LK; Campbell RK
    Ann Pharmacother; 1998 Mar; 32(3):337-48. PubMed ID: 9533065
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatotoxicity with thiazolidinediones: is it a class effect?
    Scheen AJ
    Drug Saf; 2001; 24(12):873-88. PubMed ID: 11735645
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Mechanisms and clinical effects of pioglatizone as a new agent for the treatment of type-2 diabetes].
    Paul M
    Arzneimittelforschung; 1999 Oct; 49(10):835-42. PubMed ID: 10554661
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pioglitazone (AD-4833) ameliorates insulin resistance in patients with NIDDM. AD-4833 Glucose Clamp Study Group, Japan.
    Yamasaki Y; Kawamori R; Wasada T; Sato A; Omori Y; Eguchi H; Tominaga M; Sasaki H; Ikeda M; Kubota M; Ishida Y; Hozumi T; Baba S; Uehara M; Shichiri M; Kaneko T
    Tohoku J Exp Med; 1997 Nov; 183(3):173-83. PubMed ID: 9550126
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rosiglitazone: an agent from the thiazolidinedione class for the treatment of type 2 diabetes.
    Cheng-Lai A; Levine A
    Heart Dis; 2000; 2(4):326-33. PubMed ID: 11728276
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects on lipid profile of dipeptidyl peptidase 4 inhibitors, pioglitazone, acarbose, and sulfonylureas: meta-analysis of placebo-controlled trials.
    Monami M; Vitale V; Ambrosio ML; Bartoli N; Toffanello G; Ragghianti B; Monami F; Marchionni N; Mannucci E
    Adv Ther; 2012 Sep; 29(9):736-46. PubMed ID: 22923161
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Insulin resistance-reducing effect of a new thiazolidinedione derivative, pioglitazone].
    Ikeda H; Sugiyama Y
    Nihon Yakurigaku Zasshi; 2001 May; 117(5):335-42. PubMed ID: 11411343
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose-response effect of pioglitazone on insulin sensitivity and insulin secretion in type 2 diabetes.
    Miyazaki Y; Matsuda M; DeFronzo RA
    Diabetes Care; 2002 Mar; 25(3):517-23. PubMed ID: 11874940
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial.
    Schernthaner G; Matthews DR; Charbonnel B; Hanefeld M; Brunetti P;
    J Clin Endocrinol Metab; 2004 Dec; 89(12):6068-76. PubMed ID: 15579760
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pioglitazone.
    Gillies PS; Dunn CJ
    Drugs; 2000 Aug; 60(2):333-43; discussion 344-5. PubMed ID: 10983737
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The efficacy and safety of pioglitazone hydrochloride in combination with sulphonylureas and metfomin in the treatment of type 2 diabetes mellitus a 12-week randomized multi-centres placebo-controlled parallel study].
    Pan C; Gao Y; Gao X; Li G; Luo B; Shi H; Tian H; Jia P; Lin H; Xing X; Zhao Y; Zhou L
    Zhonghua Nei Ke Za Zhi; 2002 Jun; 41(6):388-92. PubMed ID: 12137601
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of liver function in type 2 diabetic patients during clinical trials: evidence that rosiglitazone does not cause hepatic dysfunction.
    Lebovitz HE; Kreider M; Freed MI
    Diabetes Care; 2002 May; 25(5):815-21. PubMed ID: 11978674
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of pharmacokinetic and pharmacodynamic interaction between the dipeptidyl peptidase IV inhibitor vildagliptin, glyburide and pioglitazone in patients with Type 2 diabetes.
    Serra D; He YL; Bullock J; Riviere GJ; Balez S; Schwartz S; Wang Y; Ligueros-Saylan M; Jarugula V; Dole WP
    Int J Clin Pharmacol Ther; 2008 Jul; 46(7):349-64. PubMed ID: 18793589
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Glitazone--a new drug for type 2 diabetes].
    Toyota T
    Nihon Rinsho; 2002 Sep; 60 Suppl 9():422-8. PubMed ID: 12387028
    [No Abstract]   [Full Text] [Related]  

  • 19. [Clinical evaluation of pioglitazone].
    Kobayashi M; Iwata M; Haruta T
    Nihon Rinsho; 2000 Feb; 58(2):395-400. PubMed ID: 10707564
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and clinical evaluation of the alogliptin plus pioglitazone combination for type 2 diabetes.
    Scheen AJ
    Expert Opin Drug Metab Toxicol; 2015 Jun; 11(6):1005-20. PubMed ID: 25936384
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.